MaxCyte (MXCT) Competitors

Herald (LON:HRI) and MaxCyte (LON:MXCT) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings.

Which has more risk & volatility, HRI or MXCT?

Herald has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Is HRI or MXCT more profitable?

Herald has a net margin of 107.72% compared to MaxCyte's net margin of -78.37%. Herald's return on equity of 14.78% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Herald	107.72%	14.78%	9.22%
MaxCyte	-78.37%	-16.01%	-11.07%

Does the MarketBeat Community favor HRI or MXCT?

MaxCyte received 50 more outperform votes than Herald when rated by MarketBeat users. Likewise, 68.92% of users gave MaxCyte an outperform vote while only 67.76% of users gave Herald an outperform vote.

Company	Underperform	Outperform
Herald	Outperform Votes 103 67.76%	Underperform Votes 49 32.24%
MaxCyte	Outperform Votes 153 68.92%	Underperform Votes 69 31.08%

Do insiders and institutionals believe in HRI or MXCT?

31.8% of Herald shares are owned by institutional investors. Comparatively, 70.5% of MaxCyte shares are owned by institutional investors. 5.4% of Herald shares are owned by insiders. Comparatively, 1.5% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media prefer HRI or MXCT?

In the previous week, MaxCyte had 3 more articles in the media than Herald. MarketBeat recorded 3 mentions for MaxCyte and 0 mentions for Herald. Herald's average media sentiment score of -0.40 beat MaxCyte's score of -0.71 indicating that Herald is being referred to more favorably in the media.

Company	Overall Sentiment
Herald	Neutral
MaxCyte	Negative

Which has stronger earnings and valuation, HRI or MXCT?

Herald has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Herald, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Herald	£162.63M	5.80	£175.20M	£346.54	5.40
MaxCyte	£57.52M	4.43	-£45.08M	-£27.29	-7.07

Summary

Herald beats MaxCyte on 10 of the 15 factors compared between the two stocks.